Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary OphthaliX Inc. released results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist.

30 Dec 2013

FIDELITY project compares surgical treatment of degenerative meniscal tears to placebo surgery

The Finnish Degenerative Meniscal Lesion Study (FIDELITY) compared surgical treatment of degenerative meniscal tears to placebo surgery.

27 Dec 2013

CEL-SCI closes public offering of common stock, exercises over-allotment option to purchase additional shares

CEL-SCI Corporation, a late-stage oncology company, today announced that it has closed an underwritten public offering of units consisting of an aggregate of 5,238,095 shares of common stock and warrants to purchase an aggregate of 5,238,095 shares of common stock. The

27 Dec 2013

THRIL could be novel biomarker for immune activation, potential target for inflammatory diseases

Sanford-Burnham Medical Research Institute scientists have discovered a new molecule that forms when certain white blood cells-macrophages-are stimulated in response to pathogens.

27 Dec 2013

Genetics of rheumatoid arthritis contributes to biology and drug discovery

The results of the largest international study to date into the genetic basis of rheumatoid arthritis shed light on the biology of the disease and provide evidence that large-scale genetic studies can assist in the identification of new drugs for complex disorders such as rheumatoid arthritis.

26 Dec 2013

Diflunisal drug reduces neurological decline in patients with familial transthyretin amyloidosis

A recent study led by researchers from the Amyloidosis Center at Boston University School of Medicine and Boston Medical Center demonstrates that diflunisal, a generic anti-inflammatory drug, successfully reduced neurological decline and preserved the quality of life in patients with familial transthyretin amyloidosis. Diflunisal is an inexpensive and safe medication marketed over the past 40 years for arthritis and pain.

25 Dec 2013

Hospital-diagnosed maternal bacterial infections during pregnancy increase risk of autism in children

Hospital-diagnosed maternal bacterial infections during pregnancy were associated with an increased risk of autism spectrum disorders in children, according to a Kaiser Permanente study published Dec. 23 in the Journal of Autism and Developmental Disorders.

24 Dec 2013

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist.

23 Dec 2013

Death rates two times higher in postmenopausal women with anti-CCP and RA antibodies

New research shows mortality rates are two times higher in postmenopausal women with rheumatoid arthritis (RA) and anti-cyclic citrullinated peptide (anti-CCP) antibodies. Findings published in the American College of Rheumatology (ACR) journal Arthritis & Rheumatism, soon to be called Arthritis & Rheumatology, indicate the higher mortality rates persisted after adjusting for age, positive rheumatoid factor, positive antinuclear antibodies (ANA) and disease modifying anti-rheumatic drug (DMARD) use.

23 Dec 2013

Six common diseases arise from DNA changes, finds new research

Many rare disorders are caused by gene mutation, like sickle cell anemia. Yet until now the underlying genetic cause of more common conditions - for example, rheumatoid arthritis - has evaded scientists for years.

22 Dec 2013

Antares Pharma receives Notice of Allowance for new patent application on reconstitutable drugs

Antares Pharma, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent Office for application 13/584,317. This application, along with U.S. Patent 8,251,947 granted in August of 2012, relate to Antares' injector technology for wet-dry injectable drugs such as lyophilized biologicals or peptide drugs that require dry storage to assure stability.

20 Dec 2013

Solana's CrossCHECK Plating System receives FDA clearance

Solana Surgical, LLC, a growth extremity company, announces the FDA Clearance of the CrossCHECK™ Plating System, a new implant system for orthopedic and podiatric surgeons' use in foot and ankle procedures. Commercialization will follow in the first quarter of 2014.

20 Dec 2013

Hispanic mortality paradox found in RA patients

The so-called “Hispanic survival paradox” has been found to extend to patients with rheumatoid arthritis, whereby Hispanic people with the condition tend have more severe symptoms but equivalent mortality to non-Hispanic White individuals.

19 Dec 2013

Helsinn, Mundipharma sign distribution and license agreement for investigational therapy

Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution agreement, covering China, Hong Kong and Macao, for netupitant-palonosetron fixed dose combination, a Helsinn product under development for the treatment of chemotherapy-induced nausea and vomiting.

19 Dec 2013

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

Sanofi and Regeneron Pharmaceuticals, Inc. today announced an innovative collaboration with the American College of Cardiology focused on enhancing clinical research with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). PCSK9 is known to contribute to circulating low-density lipoprotein cholesterol (LDL-C) levels. Alirocumab is being co-developed by Sanofi and Regeneron.

19 Dec 2013

Regenerative medicine may offer ways to banish baldness

Regenerative medicine may offer ways to banish baldness that don't involve toupees. The lab of USC scientist Krzysztof Kobielak, MD, PhD has published a trio of papers in the journals Stem Cells and the Proceedings of the National Academy of Sciences (PNAS) that describe some of the factors that determine when hair grows, when it stops growing and when it falls out.

19 Dec 2013

People with intermittent explosive disorder elevate levels of markers of systemic inflammation in blood

People with intermittent explosive disorder — a psychiatric illness characterized by impulsivity, hostility and recurrent aggressive outbursts — have elevated levels of two markers of systemic inflammation in their blood, according to a study involving nearly 200 subjects.

19 Dec 2013

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for standard review the Company's supplemental Biologics License Application for EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema.

18 Dec 2013

Primary cilia play key role in stem cell differentiation

Researchers at Queen Mary University of London have shown for the first time that the specialised role stem cells go on to perform is controlled by primary cilia -tiny hair-like structures protruding from a cell.

18 Dec 2013

Chronic pain amongst different ethnic groups: an interview with Professor Martin Underwood, Warwick Medical School

Conventionally chronic pain is defined as pain that lasts beyond the expected period of healing. Most experts consider a pain to be chronic after three months.

18 Dec 2013

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

FIDELITY project compares surgical treatment of degenerative meniscal tears to placebo surgery

CEL-SCI closes public offering of common stock, exercises over-allotment option to purchase additional shares

THRIL could be novel biomarker for immune activation, potential target for inflammatory diseases

Genetics of rheumatoid arthritis contributes to biology and drug discovery

Diflunisal drug reduces neurological decline in patients with familial transthyretin amyloidosis

Hospital-diagnosed maternal bacterial infections during pregnancy increase risk of autism in children

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

Death rates two times higher in postmenopausal women with anti-CCP and RA antibodies

Six common diseases arise from DNA changes, finds new research

Antares Pharma receives Notice of Allowance for new patent application on reconstitutable drugs

Solana's CrossCHECK Plating System receives FDA clearance

Hispanic mortality paradox found in RA patients

Helsinn, Mundipharma sign distribution and license agreement for investigational therapy

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

Regenerative medicine may offer ways to banish baldness

People with intermittent explosive disorder elevate levels of markers of systemic inflammation in blood

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Primary cilia play key role in stem cell differentiation

Chronic pain amongst different ethnic groups: an interview with Professor Martin Underwood, Warwick Medical School

Building Bridges to Scalable Allogeneic Cell Therapy

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Building Bridges to Scalable Allogeneic Cell Therapy

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

Newsletters you may be interested in